4-Hydroperoxycyclophosphamide (BioDeep_00000713992)
Volatile Flavor Compounds
代谢物信息卡片
化学式: C7H15Cl2N2O4P (292.014646)
中文名称: 4-羟基环磷酰胺-d4, 4-氢过氧环磷酰胺
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: C1COP(=O)(NC1OO)N(CCCl)CCCl
InChI: InChI=1S/C7H15Cl2N2O4P/c8-2-4-11(5-3-9)16(13)10-7(15-12)1-6-14-16/h7,12H,1-6H2,(H,10,13)
描述信息
A phosphorodiamide that is the active metabolite of the nitrogen mustard cyclophosphamide. It has potent antineoplastic and immunosuppressive properties.
D000970 - Antineoplastic Agents > D018906 - Antineoplastic Agents, Alkylating > D009588 - Nitrogen Mustard Compounds
D000970 - Antineoplastic Agents > D018906 - Antineoplastic Agents, Alkylating > D010752 - Phosphoramide Mustards
同义名列表
数据库引用编号
7 个数据库交叉引用编号
- ChEBI: CHEBI:196991
- PubChem: 38347
- ChEMBL: CHEMBL61511
- CAS: 1246816-71-6
- CAS: 62435-42-1
- CAS: 39800-16-3
- MetaboLights: MTBLC196991
分类词条
相关代谢途径
BioCyc(0)
PlantCyc(0)
代谢反应
45 个相关的代谢反应过程信息。
Reactome(45)
- Metabolism:
2MACA-CoA + CoA ⟶ Ac-CoA + PROP-CoA
- Biological oxidations:
H+ + Oxygen + TPNH + aflatoxin B1 ⟶ AFXBO + H2O + TPN
- Phase I - Functionalization of compounds:
H+ + Oxygen + TPNH + aflatoxin B1 ⟶ AFXBO + H2O + TPN
- Metabolism:
3alpha,7alpha,12alpha-trihydroxy-5beta-cholest-24-one-CoA + CoA-SH ⟶ choloyl-CoA + propionyl CoA
- Biological oxidations:
11DCORT + H+ + Oxygen + TPNH ⟶ CORT + H2O + TPN
- Phase I - Functionalization of compounds:
11DCORT + H+ + Oxygen + TPNH ⟶ CORT + H2O + TPN
- Metabolism:
3alpha,7alpha,12alpha-trihydroxy-5beta-cholest-24-one-CoA + CoA-SH ⟶ choloyl-CoA + propionyl CoA
- Biological oxidations:
H+ + Oxygen + TPNH + aflatoxin B1 ⟶ AFXBO + H2O + TPN
- Phase I - Functionalization of compounds:
CH3CHO + H2O + NAD ⟶ CH3COO- + H+ + NADH
- Metabolism:
1-3-oxo-THA-CoA + CoA-SH ⟶ DHA-CoA + propionyl CoA
- Biological oxidations:
11DCORT + H+ + Oxygen + TPNH ⟶ CORT + H2O + TPN
- Phase I - Functionalization of compounds:
11DCORT + H+ + Oxygen + TPNH ⟶ CORT + H2O + TPN
- Metabolism:
1-3-oxo-THA-CoA + CoA-SH ⟶ DHA-CoA + propionyl CoA
- Biological oxidations:
11DCORT + H+ + Oxygen + TPNH ⟶ CORT + H2O + TPN
- Phase I - Functionalization of compounds:
11DCORT + H+ + Oxygen + TPNH ⟶ CORT + H2O + TPN
- Metabolism:
ATP + PROP-CoA + carbon dioxide ⟶ ADP + MEMA-CoA + Pi
- Biological oxidations:
H+ + Oxygen + TPNH + aflatoxin B1 ⟶ AFXBO + H2O + TPN
- Phase I - Functionalization of compounds:
CH3CHO + H2O + NAD ⟶ CH3COO- + H+ + NADH
- Metabolism:
1-3-oxo-THA-CoA + CoA-SH ⟶ DHA-CoA + propionyl CoA
- Biological oxidations:
CH3CHO + H2O + NAD ⟶ CH3COO- + H+ + NADH
- Phase I - Functionalization of compounds:
CH3CHO + H2O + NAD ⟶ CH3COO- + H+ + NADH
- Metabolism:
2MACA-CoA + CoA ⟶ Ac-CoA + PROP-CoA
- Biological oxidations:
H+ + Oxygen + TPNH + progesterone ⟶ 11DCORST + H2O + TPN
- Phase I - Functionalization of compounds:
H+ + Oxygen + TPNH + progesterone ⟶ 11DCORST + H2O + TPN
- Metabolism:
3alpha,7alpha,12alpha-trihydroxy-5beta-cholest-24-one-CoA + CoA-SH ⟶ choloyl-CoA + propionyl CoA
- Biological oxidations:
11DCORT + H+ + Oxygen + TPNH ⟶ CORT + H2O + TPN
- Phase I - Functionalization of compounds:
11DCORT + H+ + Oxygen + TPNH ⟶ CORT + H2O + TPN
- Metabolism:
1-3-oxo-THA-CoA + CoA-SH ⟶ DHA-CoA + propionyl CoA
- Biological oxidations:
11DCORT + H+ + Oxygen + TPNH ⟶ CORT + H2O + TPN
- Phase I - Functionalization of compounds:
11DCORT + H+ + Oxygen + TPNH ⟶ CORT + H2O + TPN
- Metabolism:
2MACA-CoA + CoA ⟶ Ac-CoA + PROP-CoA
- Biological oxidations:
H+ + Oxygen + TPNH + aflatoxin B1 ⟶ AFXBO + H2O + TPN
- Phase I - Functionalization of compounds:
H+ + Oxygen + TPNH + aflatoxin B1 ⟶ AFXBO + H2O + TPN
- Metabolism:
2MACA-CoA + CoA ⟶ Ac-CoA + PROP-CoA
- Biological oxidations:
11DCORT + H+ + Oxygen + TPNH ⟶ CORT + H2O + TPN
- Phase I - Functionalization of compounds:
11DCORT + H+ + Oxygen + TPNH ⟶ CORT + H2O + TPN
- Metabolism:
CAR + propionyl CoA ⟶ CoA-SH + Propionylcarnitine
- Biological oxidations:
CH3CHO + H2O + NAD ⟶ CH3COO- + H+ + NADH
- Phase I - Functionalization of compounds:
CH3CHO + H2O + NAD ⟶ CH3COO- + H+ + NADH
- Metabolism:
ATP + PROP-CoA + carbon dioxide ⟶ ADP + MEMA-CoA + Pi
- Biological oxidations:
11DCORT + H+ + Oxygen + TPNH ⟶ CORT + H2O + TPN
- Phase I - Functionalization of compounds:
11DCORT + H+ + Oxygen + TPNH ⟶ CORT + H2O + TPN
- Metabolism:
1-3-oxo-THA-CoA + CoA-SH ⟶ DHA-CoA + propionyl CoA
- Biological oxidations:
H+ + Oxygen + TPNH + aflatoxin B1 ⟶ AFXBO + H2O + TPN
- Phase I - Functionalization of compounds:
H+ + Oxygen + TPNH + aflatoxin B1 ⟶ AFXBO + H2O + TPN
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有:
- PubMed: 来源于PubMed文献库中的文献信息,我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表,这个列表按照代谢物同时出现的文献数量降序排序,取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘,得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序,取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中,存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称,可以跳转到相关代谢物的信息页面。
文献列表
- Tobie D Lee, Olivia W Lee, Kyle R Brimacombe, Lu Chen, Rajarshi Guha, Sabrina Lusvarghi, Bethilehem G Tebase, Carleen Klumpp-Thomas, Robert W Robey, Suresh V Ambudkar, Min Shen, Michael M Gottesman, Matthew D Hall. A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Molecular pharmacology.
2019 11; 96(5):629-640. doi:
10.1124/mol.119.115964
. [PMID: 31515284] - Ean-Jeong Seo, Sabine M Klauck, Thomas Efferth, Alexander Panossian. Adaptogens in chemobrain (Part II): Effect of plant extracts on chemotherapy-induced cytotoxicity in neuroglia cells.
Phytomedicine : international journal of phytotherapy and phytopharmacology.
2019 May; 58(?):152743. doi:
10.1016/j.phymed.2018.11.004
. [PMID: 30901664] - Malgorzata Opydo-Chanek, Katarzyna Śladowska, Kamil Blicharski, Jaromir Mikeš, Peter Fedoročko, Ulf Niemeyer, Lidia Mazur. Comparison of In Vitro Antileukemic Activity of 4-Hydroperoxyifosfamide and 4-Hydroperoxycyclophosphamide.
Anticancer research.
2017 11; 37(11):6355-6361. doi:
10.21873/anticanres.12088
. [PMID: 29061820] - Sua Kim, Hyo-Jung Choi, Chor Ho Jo, Joon-Sung Park, Tae-Hwan Kwon, Gheun-Ho Kim. Cyclophosphamide-induced vasopressin-independent activation of aquaporin-2 in the rat kidney.
American journal of physiology. Renal physiology.
2015 Sep; 309(5):F474-83. doi:
10.1152/ajprenal.00477.2014
. [PMID: 26109089] - Zaki S Badawy, Abdul-Kader Souid. Inhibition of human sperm respiration by 4-hydroperoxycyclophosphamide and protection by mesna and WR-1065.
Fertility and sterility.
2009 Jan; 91(1):173-8. doi:
10.1016/j.fertnstert.2007.11.008
. [PMID: 18206143] - Monish Jain, Junying Fan, Nesrine Z Baturay, Chul-Hoon Kwon. Sulfonyl-containing aldophosphamide analogues as novel anticancer prodrugs targeted against cyclophosphamide-resistant tumor cell lines.
Journal of medicinal chemistry.
2004 Jul; 47(15):3843-52. doi:
10.1021/jm0304764
. [PMID: 15239662] - D E Reece, D A Brockington, G L Phillips, M J Barnett, H G Klingemann, S H Nantel, H J Sutherland, J D Shepherd. Prolonged survival after intensive therapy and purged ABMT in patients with multiple myeloma.
Bone marrow transplantation.
2000 Sep; 26(6):621-6. doi:
10.1038/sj.bmt.1702574
. [PMID: 11041567] - B A Roecklein, J Reems, S Rowley, B Torok-Storb. Ex vivo expansion of immature 4-hydroperoxycyclophosphamide-resistant progenitor cells from G-CSF-mobilized peripheral blood.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
1998; 4(2):61-8. doi:
10.1053/bbmt.1998.v4.pm9763108
. [PMID: 9763108] - B A Teicher, Y Kakeji, G Ara, R S Herbst, D Northey. Prostate carcinoma response to cytotoxic therapy: in vivo resistance.
In vivo (Athens, Greece).
1997 Nov; 11(6):453-61. doi:
NULL
. [PMID: 9509295] - L Sreerama, N E Sladek. Identification and characterization of a novel class 3 aldehyde dehydrogenase overexpressed in a human breast adenocarcinoma cell line exhibiting oxazaphosphorine-specific acquired resistance.
Biochemical pharmacology.
1993 Jun; 45(12):2487-505. doi:
10.1016/0006-2952(93)90231-k
. [PMID: 8328987] - J M Schuster, H S Friedman, G E Archer, H E Fuchs, R E McLendon, O M Colvin, D D Bigner. Intraarterial therapy of human glioma xenografts in athymic rats using 4-hydroperoxycyclophosphamide.
Cancer research.
1993 May; 53(10 Suppl):2338-43. doi:
NULL
. [PMID: 8485721] - D E Reece, M J Barnett, J M Connors, H G Klingemann, S E O'Reilly, J D Shepherd, H J Sutherland, G L Phillips. Treatment of multiple myeloma with intensive chemotherapy followed by autologous BMT using marrow purged with 4-hydroperoxycyclophosphamide.
Bone marrow transplantation.
1993 Feb; 11(2):139-46. doi:
NULL
. [PMID: 8435663] - F M Uckun, S Haissig, J A Ledbetter, P Fidler, D E Myers, V Kuebelbeck, D Weisdorf, K Gajl-Peczalska, J H Kersey, N K Ramsay. Developmental hierarchy during early human B-cell ontogeny after autologous bone marrow transplantation using autografts depleted of CD19+ B-cell precursors by an anti-CD19 pan-B-cell immunotoxin containing pokeweed antiviral protein.
Blood.
1992 Jun; 79(12):3369-79. doi:
NULL
. [PMID: 1375851] - M Towatari, Y Ito, Y Morishita, M Tanimoto, K Kawashima, Y Morishima, T Andoh, H Saito. Enhanced expression of DNA topoisomerase II by recombinant human granulocyte colony-stimulating factor in human leukemia cells.
Cancer research.
1990 Nov; 50(22):7198-202. doi:
NULL
. [PMID: 1699657] - H Blomgren, M Hallström. Possible role of acrolein in oxazaphosphorine-induced enhancement of immunological reactivity.
Cancer immunology, immunotherapy : CII.
1990; 31(4):221-5. doi:
10.1007/bf01789172
. [PMID: 2143101] - A Noseda, M E Berens, J G White, E J Modest. In vitro antiproliferative activity of combinations of ether lipid analogues and DNA-interactive agents against human tumor cells.
Cancer research.
1988 Apr; 48(7):1788-91. doi:
"
. [PMID: 3349458] - K M Ataya, E F Pydyn, A G Sacco. Effect of 'activated' cyclophosphamide on mouse oocyte in vitro fertilization and cleavage.
Reproductive toxicology (Elmsford, N.Y.).
1988; 2(2):105-9. doi:
10.1016/0890-6238(88)90005-6
. [PMID: 2980403] - C A Arndt, O M Colvin, F M Balis, C M Lester, G Johnson, D G Poplack. Intrathecal administration of 4-hydroperoxycyclophosphamide in rhesus monkeys.
Cancer research.
1987 Nov; 47(22):5932-4. doi:
. [PMID: 3664493]
- C G Frondoza, S Sinha, S M Trivedi, R L Humphrey, O M Colvin. Detection of residual murine LPC-1 myeloma cells from bone marrow cell mixture after purging by 4-hydroperoxycyclophosphamide.
Experimental hematology.
1987 Jul; 15(6):715-8. doi:
NULL
. [PMID: 3297761] - P Hervé, M Flesch. [Cellular sorting methods in autologous (elimination of residual malignant cells) or allogeneic (T lymphocyte elimination) bone marrow grafts. Clinical pilot studies].
Nouvelle revue francaise d'hematologie.
1986; 28(2):97-105. doi:
"
. [PMID: 2942838] - H Zincke, I Jardine, M Colvin, G Aydin, S E Okiye. In vitro alteration of canine renal allografts with cyclophosphamide metabolites.
Transplantation proceedings.
1983 Jun; 15(2):1698-701. doi:
NULL
. [PMID: 6349051] - J E Low, R F Borch, N E Sladek. Conversion of 4-hydroperoxycyclophosphamide and 4-hydroxycyclophosphamide to phosphoramide mustard and acrolein mediated by bifunctional catalysis.
Cancer research.
1982 Mar; 42(3):830-7. doi:
. [PMID: 7059981]
- N Brock, J Pohl, J Stekar. Studies on the urotoxicity of oxazaphosphorine cytostatics and its prevention--I. Experimental studies on the urotoxicity of alkylating compounds.
European journal of cancer.
1981 Jun; 17(6):595-607. doi:
10.1016/0014-2964(81)90261-9
. [PMID: 7308258] - T Diamantstein, M Klos, H Hahn, S H Kaufmann. Direct in vitro evidence for different susceptibilities to 4-hydroperoxycyclophosphamide of antigen-primed T cells regulating humoral and cell-mediated immune responses to sheep erythrocytes: a possible explanation for the inverse action of cyclophosphamide on humoral and cell-mediated immune responses.
Journal of immunology (Baltimore, Md. : 1950).
1981 May; 126(5):1717-9. doi:
NULL
. [PMID: 6452475]